HRMY (Harmony Biosciences Holdings) Total Inventories : $7.2 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Harmony Biosciences Holdings Total Inventories?

Harmony Biosciences Holdings's total inventories for the quarter that ended in Dec. 2024 was $7.2 Mil. Harmony Biosciences Holdings's average total inventories from the quarter that ended in Sep. 2024 to the quarter that ended in Dec. 2024 was $7.1 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Harmony Biosciences Holdings's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $3.38.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Harmony Biosciences Holdings's Days Inventory for the three months ended in Dec. 2024 was 11.83.

Inventory Turnover measures how fast the company turns over its inventory within a year. Harmony Biosciences Holdings's Inventory Turnover for the quarter that ended in Dec. 2024 was 7.71.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Harmony Biosciences Holdings's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.04.

Harmony Biosciences Holdings Total Inventories Historical Data

The historical data trend for Harmony Biosciences Holdings's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harmony Biosciences Holdings Total Inventories Chart

Harmony Biosciences Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Inventories

Get a 7-Day Free Trial

3.82

4.43

4.30

5.36

7.20

Harmony Biosciences Holdings Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Inventories	Get a 7-Day Free Trial															5.36	5.86	5.64	6.92	7.20

Harmony Biosciences Holdings Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Harmony Biosciences Holdings (NAS:HRMY) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Harmony Biosciences Holdings's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is

	Net-Net Working Capital Per Share (Q: Dec. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(467.186	+	0.75 * 83.033	+	0.5 * 7.198	-	340.045
-	0	-	0)	/	57.145
=	3.38

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Harmony Biosciences Holdings's Days Inventory for the three months ended in Dec. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2024 )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
	=	7.0565	/	54.409	*	365 / 4
	=	11.83

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Harmony Biosciences Holdings's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2024 )	/	Average Total Inventories (Q: Dec. 2024 )
	=	54.409	/	7.0565
	=	7.71

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Harmony Biosciences Holdings's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	7.0565	/	201.267
	=	0.04

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Harmony Biosciences Holdings Total Inventories Related Terms

Thank you for viewing the detailed overview of Harmony Biosciences Holdings's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Harmony Biosciences Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harmony Biosciences Holdings Inc (NAS:HRMY) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 West Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462

Website

https://www.harmonybiosciences.com

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

Executives

Jeffrey Dierks	officer: Chief Commercial Officer	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Sandip Kapadia	officer: Chief Financial Officer	450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
Jeffrey M. Dayno	officer: Chief Medical Officer	460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Marshman Fund Trust Ii	10 percent owner	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Valor Iv Pharma Holdings, Llc	10 percent owner	875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Peter Anastasiou	director	C/O HARMONY BIOSCIENCES HOLDINGS, INC., 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Andreas Wicki	director	C/O HBM BIOVENTURES (CAYMAN) LTD., CENTENNIAL TOWERS,STE.305,2454 W.BAY RD., GRAND CAYMAN E9 E9
Jack Nielsen	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Andrew Serafin	officer: Chief Business Officer	630 W. GERMANTOWN PIKE, PLYMOUTH MEETING PA 19462
John C Jacobs	director, officer: President, CEO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Linda M Szyper	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Eric L Motley	director	1516 33RD STREET NW, WASHINGTON DC 20007
R. Mark Graf	director	C/O DISCOVER FINANCIAL SERVICES, 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Valor Management L.p.	10 percent owner	875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611